Search results for " lip"

showing 10 items of 1180 documents

Effects of dietary fiber intake on risk factors for cardiovascular disease in subjects at high risk

2009

Background: Epidemiological studies and feeding trials with supplements suggest that fibre intake is associated with a reduction in cardiovascular risk. However, the effects of changes in dietary fibre on risk factor levels have not been evaluated in free-living individuals. Thus, the effects of changes in dietary fibre intake on cardiovascular risk factors were assessed over 3 months in free-living high-risk subjects. Methods: 772 high-risk subjects (age 69±5 years) were assigned to a low-fat diet or two Mediterranean-style diets. All participants received behavioural and nutritional education, including recommendations for increasing the consumption of vegetables, fruits, and legumes. Cha…

Blood GlucoseMale030309 nutrition & dieteticsEpidemiologyBlood lipidsPhysiology030204 cardiovascular system & hematologyDiet Mediterraneanchemistry.chemical_compound0302 clinical medicineHigh-density lipoproteinUNESCO::CIENCIAS MÉDICAS ::Salud públicaDiet Fat-Restricted2. Zero hunger0303 health sciencesEvidence-Based MedicineMiddle Aged:CIENCIAS MÉDICAS [UNESCO]Cardiovascular diseaseDietary fiberHigh risk subjects3. Good healthC-Reactive ProteinCardiovascular diseasesCholesterolEstudi de casosCardiovascular DiseasesUNESCO::CIENCIAS MÉDICASCohortCytokinesFemalemedicine.medical_specialtyWaistDiet therapyC-reactive proteinARTHEROSCLEROSIS03 medical and health sciencesInternal medicinemedicineFibra alimentàriaHumans:CIENCIAS MÉDICAS ::Salud pública [UNESCO]Blood glucoseDietary fiber ; Risk factors ; Cardiovascular disease ; High risk subjectsRisk factorEpidemiologiaAgedNutritionCholesterolbusiness.industryMalalties cardiovascularsCholesterol HDLPublic Health Environmental and Occupational HealthCholesterol LDLAtherosclerosisBlood pressureEndocrinologychemistryRisk factorsCase studiessense organsbusinessEnergy Intake
researchProduct

Impact of a Mediterranean Dietary Pattern and Its Components on Cardiovascular Risk Factors, Glucose Control, and Body Weight in People with Type 2 D…

2018

This study evaluates the relation of a Mediterranean dietary pattern and its individual components with the cardiovascular risk factors profile, plasma glucose and body mass index (BMI) in people with type 2 diabetes. We studied 2568 participants at 57 diabetes clinics. Diet was assessed with the EPIC (European Prospective Investigation into Cancer and Nutrition) questionnaire, adherence to the Mediterranean diet was evaluated with the relative Mediterranean diet score (rMED). A high compared to a low score was associated with a better quality of diet and a greater adherence to the nutritional recommendations for diabetes. However, even in the group achieving a high score, only a small prop…

Blood GlucoseMaleMediterranean diet; cardiovascular risk; diabetes; glucose control; plasma lipids; relative Mediterranean diet score; Aged; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Glycated Hemoglobin A; Humans; Lipids; Male; Middle Aged; Nutritive Value; Patient Compliance; Protective Factors; Recommended Dietary Allowances; Risk Factors; Body Mass Index; Diet Healthy; Diet Mediterranean; Feeding BehaviorGlycated Hemoglobin AMediterranean dietRecommended Dietary AllowanceCross-sectional studyHealthy DietSaturated fatBlood PressureType 2 diabetes030204 cardiovascular system & hematologyMediterraneanDiet MediterraneanDiabeteRecommended Dietary AllowancesSettore MED/13 - EndocrinologiaBody Mass Indexchemistry.chemical_compound0302 clinical medicineRisk FactorsCardiovascular Disease030212 general & internal medicineNutrition and DieteticsdiabetesLipidMiddle AgedLipidsEuropean Prospective Investigation into Cancer and NutritionCardiovascular DiseasesFemaleDiet Healthylcsh:Nutrition. Foods and food supplyNutritive ValueType 2Humancardiovascular riskCardiovascular risk; Diabetes; Glucose control; Mediterranean diet; Plasma lipids; Relative mediterranean diet score; Aged; Biomarkers; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Cross-Sectional Studies; Diabetes Mellitus Type 2; Female; Glycated Hemoglobin A; Humans; Lipids; Male; Middle Aged; Nutritive Value; Patient Compliance; Protective Factors; Recommended Dietary Allowances; Risk Factors; Body Mass Index; Diet Mediterranean; Feeding Behavior; Healthy Diet; Food Science; Nutrition and DieteticsPlasma lipidlcsh:TX341-641Article03 medical and health sciencesEnvironmental healthDiabetes mellitusMediterranean dietplasma lipidsmedicineDiabetes MellitusHumansProtective FactorAgedCross-Sectional StudieGlycated Hemoglobinglucose controlHealthybusiness.industryRisk FactorBiomarkerFeeding Behaviorrelative Mediterranean diet scoreProtective Factorsmedicine.diseaseDietCross-Sectional StudieschemistryDiabetes Mellitus Type 2Patient ComplianceGlycated hemoglobinbusinessBody mass indexBiomarkersFood Science
researchProduct

POSTPRANDIAL HYPERGLYCEMIA IS A DETERMINANT OF PLATELET ACTIVATION IN EARLY 2 DIABETES MELLITUS

2010

BACKGROUND: Chronic hyperglycemia is a major contributor to in vivo platelet activation in diabetes mellitus. OBJECTIVES: To evaluate the effects of acarbose, an alpha-glucosidase inhibitor, on platelet activation and its determinants in newly diagnosed type 2 diabetic patients. METHODS: Forty-eight subjects (26 males, aged 61 +/- 8 years) with early type 2 diabetes (baseline hemoglobin A(1c) < or = 7% and no previous hypoglycemic treatment) were randomly assigned to acarbose up to 100 mg three times a day or placebo, and evaluated every 4 weeks for 20 weeks. The main outcome measures were urinary 11-dehydro-thromboxane (TX)B(2) (marker of in vivo platelet activation) and 8-iso-prostaglandi…

Blood GlucoseMaleTime FactorsSettore MED/09 - Medicina InternaDinoprostpostprandial hyperglycemia; platelet activationMedicineEnzyme InhibitorsSettore MED/49 - Scienze Tecniche Dietetiche Applicatepostprandial hyperglycemiaAcarboseplateletHemoglobin AHematologyMiddle AgedPostprandial PeriodP-SelectinPostprandialTreatment OutcomeC-Reactive ProteinItalyFemaleBiological MarkersAcarboseType 2medicine.drugacarbose platelet activation postprandial hyperglycemia type 2 diabetes mellitusmedicine.medical_specialtySettore BIO/14 - FARMACOLOGIAUrinary systemCD40 LigandGlycosylatedArginineExcretionBlood Glucose; Time Factors; Lipid Peroxidation; Middle Aged; Hemoglobin A Glycosylated; Postprandial Period; Diabetes Mellitus Type 2; Enzyme Inhibitors; Hypoglycemic Agents; P-Selectin; Platelet Activation; Aged; CD40 Ligand; Treatment Outcome; Male; Female; Thromboxane B2; Dinoprost; Italy; Arginine; Acarbose; Double-Blind Method; Humans; Biological Markers; Hyperglycemia; alpha-Glucosidases; C-Reactive ProteinDouble-Blind MethodInternal medicineDiabetes mellitusDiabetes MellitusHypoglycemic AgentsHumansGlycoside Hydrolase InhibitorsPlatelet activationGlycemicAgedGlycated Hemoglobinbusiness.industryType 2 Diabetes Mellitusalpha-Glucosidasesmedicine.diseasePlatelet ActivationThromboxane B2EndocrinologyDiabetes Mellitus Type 2HyperglycemiaLipid PeroxidationbusinessBiomarkers
researchProduct

Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: Results of the randomized, double-blind, placebo-controll…

2009

High-density-lipoproteins-cholesterol (HDL-C) is invertedly related to the incidence of cardiovascular events. Recent studies suggest that HDL-C directly improves endothelial function. Nicotinic acid (niacin) effectively raises serum HDL-C. We therefore hypothesized that treatment with niacin improves endothelial dysfunction in patients with coronary artery disease (CAD). One hundred seven patients with CAD were randomly assigned to double-blinded treatment for 12 weeks with extended-release (ER)-niacin 1000 mg/day (N) or placebo (C), respectively. Flow-mediated dilation (FMD) of the brachial artery, nitroglycerin-mediated endothelium-independent dilation (NMD) and serum lipid concentration…

Blood GlucoseMalemedicine.medical_specialtyBrachial ArteryVasodilator AgentsAdministration OralCoronary Artery DiseasePlaceboNiacinGastroenterologyCoronary artery diseaseNitroglycerinchemistry.chemical_compoundHigh-density lipoproteinDouble-Blind MethodInternal medicinemedicine.arterymedicineHumansProspective StudiesPhosphorylationEndothelial dysfunctionBrachial arteryTriglyceridesAgedUltrasonographyVascular diseasebusiness.industryCholesterol HDLMicrofilament Proteinsnutritional and metabolic diseasesCholesterol LDLMiddle AgedPhosphoproteinsmedicine.diseaseVasodilationB vitaminsTreatment OutcomeEndocrinologychemistryDelayed-Action PreparationsFemalelipids (amino acids peptides and proteins)Endothelium VascularCardiology and Cardiovascular MedicinebusinessCell Adhesion MoleculesBiomarkersNiacinAtherosclerosis
researchProduct

Plasma glycosphingolipids in diabetics and normals

1975

In diabetic patients with hyperlipoproteinemia type IV the monohexosyl ceramide concentration in blood plasma is significantly elevated. This augmentation can be attributed to an increased monohexosyl ceramide content of the BLDL plasma fraction. In contrast, the di-, tri-, the tetrahexosyl ceramide levels remain within normal limits. In normolipidemic diabetics of comparable age, sex, and weight classes and of comparable metabolic control no elevations of glycolipid fractions could be found. However, patients with primary hyperlipoproteinemia type IV show an increase of monohexosyl ceramide concentrations in blood plasma. Therefore, the augmentation of monohexosyl ceramide levels in plasma…

Blood GlucoseMalemedicine.medical_specialtyCeramideVery low-density lipoproteinHyperlipidemiasLipoproteins VLDLCeramidesGlycosphingolipidsDiabetes Complicationschemistry.chemical_compoundGlycolipidInternal medicineDiabetes mellitusDrug DiscoveryBlood plasmaDiabetes MellitusmedicineHumansObesityTriglyceridesGenetics (clinical)HexosesChemistrynutritional and metabolic diseasesGeneral MedicineMiddle Agedmedicine.diseaseMolecular medicineNormal limitEndocrinologyMetabolic control analysisMolecular MedicineFemaleGlycolipidsKlinische Wochenschrift
researchProduct

Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome

2009

Summary Objective  Small, dense low-density lipoproteins (LDL) are a feature of the metabolic syndrome (MS) but their predictive role still remains to be established. We performed a 2-year follow-up study in 124 subjects with MS (63 ± 6 years), as defined by the American Heart Association/National Heart, Lung and Blood Institute guidelines, to assess clinical and biochemical predictors of cerebro- and cardio-vascular events. Methods and results  Beyond traditional cardiovascular risk factors, we measured LDL size and subclasses by gradient gel electrophoresis. Clinical events were registered in the 25% of subjects. At univariate analysis subjects with events had increased prevalence of elev…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism10265 Clinic for Endocrinology and Diabetology610 Medicine & healthCerebroCoronary artery diseaseEndocrinologyPredictive Value of TestsRisk FactorsInternal medicinemedicineHumansFamily historyLow-density lipoproteins (LDL metabolic syndromeAgedMetabolic SyndromeUnivariate analysisbusiness.industryMiddle Agedmedicine.disease1310 EndocrinologyLipoproteins LDL2712 Endocrinology Diabetes and MetabolismEndocrinologymedicine.anatomical_structureSmall dense low-density lipoproteins cardio events cerebro-vascular events the metabolic syndromeCardiovascular DiseasesPredictive value of testsCirculatory systemFemaleMetabolic syndromebusinessBlood vesselFollow-Up Studies
researchProduct

Requirements for claims of favorable effects on serum lipids by oral antidiabetic agents.

1998

Blood GlucoseMalemedicine.medical_specialtymedicine.medical_treatmentBlood lipidsHyperlipidemiasBioinformaticsDiabetes ComplicationsOral administrationInternal medicineDiabetes mellitusmedicineDiabetes MellitusHumansHypoglycemic AgentsAntidiabetic agentsChemotherapybusiness.industryDrugs Investigationalmedicine.diseaseLipidsEndocrinologyCardiologyFemaleCardiology and Cardiovascular MedicinebusinessThe American journal of cardiology
researchProduct

The changes of lipid metabolism in advanced renal cell carcinoma patients treated with everolimus: a new pharmacodynamic marker?

2015

Background: Everolimus is a mammalian target of rapamycin (mTOR) inhibitor approved for the treatment of metastatic renal cell carcinoma (mRCC). We aimed to assess the association between the baseline values and treatmentrelated modifications of total serum cholesterol (C), triglycerides (T), body mass index (BMI), fasting blood glucose level (FBG) and blood pressure (BP) levels and the outcome of patients treated with everolimus for mRCC. Methods: 177 patients were included in this retrospective analysis. Time to progression (TTP), clinical benefit (CB) and overall survival (OS) were evaluated. Results: Basal BMI was significantly higher in patients who experienced a CB (p=0,0145). C, T an…

Blood Glucoselcsh:MedicineBlood Pressureurologic and male genital diseasesTriglycerideBody Mass IndexAntineoplastic Agentchemistry.chemical_compoundRetrospective StudieRenal cell carcinomalcsh:ScienceMultidisciplinaryKidney NeoplasmKidney NeoplasmsSurvival RateEverolimuCholesterolDisease ProgressionHumanmedicine.drugResearch ArticleAdultmedicine.medical_specialtyAdolescentUrologyBlood sugarAntineoplastic AgentsYoung AdultInternal medicinemedicineCarcinomaHumansEverolimusCarcinoma Renal CellTriglyceridesNeoplasm StagingRetrospective StudiesBiochemistry Genetics and Molecular Biology (all)EverolimusCholesterolbusiness.industrylcsh:RCarcinomaRenal CellAdolescent; Adult; Antineoplastic Agents; Biomarkers; Blood Glucose; Blood Pressure; Body Mass Index; Carcinoma Renal Cell; Cholesterol; Disease Progression; Everolimus; Humans; Kidney Neoplasms; Lipid Metabolism; Neoplasm Staging; Retrospective Studies; Survival Rate; Triglycerides; Young Adult; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Lipid metabolismBiomarkermedicine.diseaseLipid Metabolismrenal; carcinomaBlood pressureEndocrinologyAgricultural and Biological Sciences (all)chemistryPharmacodynamicslcsh:QbusinessBiomarkersPloS one
researchProduct

The effects of 12-week progressive strength training on strength, functional capacity, metabolic biomarkers, and serum hormone concentrations in heal…

2018

Previous findings suggest that performing strength training (ST) in the evening may provide greater benefit for young individuals. However, this may not be optimal for the older population. The purpose of this study was to compare the effects of a 12-week ST program performed in the morning vs. evening on strength, functional capacity, metabolic biomarker and basal hormone concentrations in older women. Thirty-one healthy older women (66 ± 4 years, 162 ± 4 cm, 75 ± 13 kg) completed the study. Participants trained in the morning (M) (07:30, n = 10), in the evening (E) (18:00, n = 10), or acted as a non-training control group (C) (n = 11). Both intervention groups performed whole-body strengt…

Blood Glucosemaximum strengthmedicine.medical_specialtyEveningWeight LiftingPhysiologyStrength trainingRestBlood lipidsMuscle hypertrophysenior fitness testsresistance03 medical and health sciencesFollicle-stimulating hormone0302 clinical medicinePhysiology (medical)Internal medicinemedicineHumanstime of the dayTestosteroneMuscle StrengthLeg pressMuscle Skeletalta315vuorokaudenajatMorningAgedblood lipidsbusiness.industryagingResistance Training030229 sport sciencesCircadian RhythmharjoitusvasteEndocrinologyikääntyminenFemalevoimaharjoitteluLuteinizing hormonebusiness030217 neurology & neurosurgeryBiomarkersikääntyneetChronobiology International
researchProduct

ENDOCRINE SIDE EFFECTS OF ANTI-CANCER DRUGS: Effects of anti-cancer targeted therapies on lipid and glucose metabolism

2014

During the past years, targeted therapies for cancer have been developed using drugs that have significant metabolic consequences. Among them, the mammalian target of rapamycin (mTOR) inhibitors and, to a much lesser extent, the tyrosine kinase inhibitors (TKIs) are involved. mTOR plays a key role in the regulation of cell growth as well as lipid and glucose metabolism. Treatment with mTOR inhibitors is associated with a significant increase in plasma triglycerides and LDL cholesterol. mTOR inhibitors seem to increase plasma triglycerides by reducing the activity of the lipoprotein lipase which is in charge of the catabolism of triglyceride-rich lipoproteins. The increase in LDL cholesterol…

Blood Glucosemedicine.medical_specialtyEndocrinology Diabetes and MetabolismAntineoplastic AgentsHypoglycemiaCarbohydrate metabolismBiologyEndocrinologyInsulin resistanceInternal medicineHyperlipidemiamedicineHomeostasisHumansGlucose homeostasisEnzyme InhibitorsTriglyceridesPI3K/AKT/mTOR pathwayLipoprotein lipaseTOR Serine-Threonine KinasesGeneral MedicineProtein-Tyrosine KinasesLipid Metabolismmedicine.diseaseEndocrinologyLDL receptorCarbohydrate MetabolismEuropean Journal of Endocrinology
researchProduct